Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
May 22, 2020
New Longer-Term Safety Data of Chugai’s Satralizumab in Adults and Adolescents with Neuromyelitis Optica Spectrum Disorder Presented at EAN
TOKYO, May 22, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release regarding the new longer-term safety data of satralizumab (development code: SA237) for the treatment of adults and adolescents with neuromyelitis optica spectrum disorder presented at the 6th Annual Meeting of the European Academy of Neurology. Satralizumab is an anti-IL-6 receptor recycling antibody created by Chugai.
Please refer to the link below for details of the press release:
- New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder
- https://www.roche.com/media/releases/med-cor-2020-05-22.htm
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Toshiya Sasai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
